Abstract Search

ea0035p914 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Octreotide fluid crystal provides sustained octreotide bioavailability and similar IGF1 suppression to that of octreotide LAR (Sandostatin LAR): randomized, open-label, Phase I, repeat-dose study in healthy volunteers

Roberts John , Linden Margareta , Cervin Camilla , Tiberg Fredrik

Background: Octreotide is the most widely used somatostatin analogue; however, the LAR formulation must be reconstituted prior to intramuscular injection. This Phase I study compared the pharmacokinetics and pharmacodynamics of octreotide Fluid Crystal (FC), a ready-to-use depot formulation for s.c. administration, vs octreotide LAR.Methods: After a single dose of octreotide s.c. 200 μg, healthy adult male/female volunteers were randomized 1 week la...

2 shares

Endocrine Abstracts

Octreotide fluid crystal provides sustained octreotide bioavailability and similar IGF1 suppression to that of octreotide LAR (Sandostatin LAR): randomized, open-label, Phase I, repeat-dose study in healthy volunteers

BiosciAbstracts